Quick answer: The BDI-II (Beck Depression Inventory-II) is a 21-item, 0–63 self-report depression measure with bands of minimal (0–13), mild (14–19), moderate (20–28), and severe (29–63). The PHQ-9 is a 9-item, 0–27 screener mapping to DSM-5 criteria. Both detect depression well; PHQ-9 is free and faster, while BDI-II is copyrighted, longer, and preferred in psychiatry and clinical trials for its granular severity tracking.
Interactive Beck Score Calculator
Enter the total score from your administered BDI-II (Beck Depression Inventory-II) — get the severity band and a SOAP-ready summary
Free AI screening
Neuraline's free PHQ-9 and GAD-7 AI screening tools auto-score depression and anxiety in seconds — try them free in the live demo.
Educational interpreter only — this tool does not reproduce Beck inventory test items. Bands are the standard published severity ranges; interpretation requires the administering clinician.
What Is the Beck Depression Inventory?
The Beck Depression Inventory is the oldest and most researched self-report measure of depressive severity. Aaron T. Beck published the original in 1961; the BDI-II revision followed in 1996, rewriting the somatic items (sleep, appetite, fatigue, concentration) to reduce confounding with medical illness and updating item content to match contemporary diagnostic thinking. The result is the 21-item form in use today: each item presents four graded statements rated 0–3, covering affective, cognitive, somatic, and motivational symptoms, completed in roughly 5–10 minutes.
The BDI-II's research pedigree is unmatched — it has served as the outcome measure in thousands of depression trials since the 1960s, which is precisely why psychiatry practices and research protocols still reach for it: a BDI-II score connects a patient to that entire literature. The catch is commercial: the instrument is copyrighted by Pearson, and clinical use requires purchasing licensed record forms or scoring software, with per-use costs that scale with patient volume.
BDI-II Scoring: 0–63 Total
Scoring is a straight sum of all 21 items — no reverse-scored items, no corrections:
| Step | Calculation |
|---|---|
| Item scores | Each of the 21 items rated 0, 1, 2, or 3 |
| Total score | Sum of all 21 items |
| Possible range | 0 (no symptoms) to 63 (all symptoms at maximum severity) |
Two scoring rules: verify the form is complete before banding (a skipped item understates severity), and remember the recall window is the past two weeks. Item 9 (thoughts of death or suicide) gets individual review regardless of the total — any nonzero endorsement triggers a suicide risk assessment independent of the band.
Severity Bands Side by Side
| Instrument | Minimal | Mild | Moderate | Severe |
|---|---|---|---|---|
| BDI-II (0–63) | 0–13 | 14–19 | 20–28 | 29–63 |
| PHQ-9 (0–27) | 0–4 | 5–9 | 10–14 | 15–19 moderately severe / 20–27 severe |
The band structures differ by design. The BDI-II uses four bands across a 0–63 range; the PHQ-9 uses five across 0–27, splitting the top into "moderately severe" and "severe." The scores are not interchangeable — a BDI-II 20 and a PHQ-9 20 are different severities — but rough cross-instrument equivalence exists: a BDI-II in the mid-teens (mild) corresponds approximately to a PHQ-9 around 10 (the positive-screen cutoff), and a BDI-II near 29 (severe) corresponds roughly to a PHQ-9 in the high teens to low 20s. Treat these as anchors for case discussion, never as exact conversions.
BDI-II vs PHQ-9: Head-to-Head
| BDI-II | PHQ-9 | |
|---|---|---|
| Items | 21 | 9 |
| Completion time | 5–10 min | ~3 min |
| Score range | 0–63 | 0–27 |
| Bands | 4 (minimal/mild/moderate/severe) | 5 (minimal → severe) |
| Licensing | Pearson — paid forms/scoring software | Free for clinical use |
| DSM-5 mapping | Predates DSM-5; symptom-based | Maps 1:1 to DSM-5 MDD criteria |
| Suicide-risk item | Item 9 (thoughts of death/suicide) + item 2 (pessimism) | Item 9 (self-harm/death wishes) |
| Somatic confounding | Reduced in BDI-II revision | Notable in medically ill patients |
| Translations | Dozens of validated versions | 30+ validated translations |
| Best fit | Psychiatry, clinical trials, research | Primary care, behavioral health, measurement-based care |
The licensing difference is the practical dividing line. The BDI-II requires purchasing Pearson record forms or scoring software — a real per-use cost that compounds with patient volume — while the PHQ-9 is free to use in clinical practice without licensing fees (Pfizer holds the copyright but permits free clinical use). For a primary-care clinic screening hundreds of patients monthly, that difference alone decides the question.
Accuracy is not the differentiator. At its ≥10 cutoff the PHQ-9 achieves roughly 88% sensitivity and 88% specificity for major depressive disorder; the BDI-II's psychometrics are comparable, with internal consistency around 0.9 in psychiatric samples. Both are excellent severity measures — neither is a diagnostic instrument, and both require clinical confirmation against DSM-5-TR criteria.
The structural difference is DSM alignment. The PHQ-9 was built as the self-report arm of PRIME-MD, with its nine items corresponding directly to the nine DSM-5 major-depression criteria — which is why payers, CMS quality programs, and most EHR workflows recognize it. The BDI-II predates the DSM-5 and measures symptom severity on its own conceptual axes; it is not criterion-mapped, which is a feature for research granularity and a friction point for payer-facing documentation.
Which Should Your Practice Use?
- Primary care and family medicine: PHQ-9. Free, 3 minutes, payer-recognized, criterion-mapped, and the default in every CMS quality measure that involves depression screening and follow-up.
- Psychiatry and specialty behavioral health: either — many practices screen with the free PHQ-9 and add the BDI-II for patients needing granular severity tracking, or use the BDI-II throughout to preserve comparability with prior records and the research literature.
- Clinical trials and research: BDI-II. Its 0–63 range and decades of published baselines make it the standard outcome measure; switching instruments mid-study breaks comparability.
- Measurement-based care at scale: PHQ-9. The economics of serial administration — every 2–4 weeks across an entire panel — only work with a free instrument unless the practice bills 96127 systematically.
The honest summary: the BDI-II is the better research instrument and the more expensive clinical one; the PHQ-9 is the better clinical workflow instrument. Most US practices end up with the PHQ-9 not because it is psychometrically superior — it is not — but because free, fast, and payer-aligned beats granular when the task is screening a whole panel.
Using Scores in Measurement-Based Care
Whichever instrument you choose, the value comes from serial administration:
- Cadence: every 2–4 weeks during active treatment, at a consistent point in the visit cycle.
- Response: commonly defined as a ≥50% reduction from baseline; remission as a return below the mild cutoff (PHQ-9 below 10, BDI-II at or below 13).
- Documentation: record the raw score, the band, and the trend at every administration — this is what supports CPT 96127 billing (staff-administered scoring, roughly $1.50–$3 per administration) and what demonstrates medical necessity for continued treatment.
- Safety: PHQ-9 item 9 or BDI-II item 9 nonzero → suicide risk assessment, regardless of the total.
Doing this manually for every patient is where the workflow breaks — which is the problem Neuraline's AI Screening solves: the PHQ-9 and GAD-7 are administered automatically before the appointment through Digital Forms sent via the patient portal, scored instantly, flagged for item-9 risk, and filed into the chart with the trend visible at the next visit. No staff scoring time, no per-use licensing, no missed administrations. See it in the live demo.
FAQs
Is the BDI the same as the Beck Depression Scale? Yes — Beck Depression Scale, BDI, BDI-IA, and BDI-II all refer to the Beck family of depression inventories. The BDI-II (1996) is the current clinical version; older published cutoffs differ slightly, so always score against the version actually administered.
What is a normal BDI-II score? Scores of 0–13 fall in the minimal range and are generally considered normal. There is no single "normal" value below 14 — a stable low score under treatment is a good sign, while a rising trend within the minimal band still deserves attention.
Is the BDI-II free to use? No. The BDI-II is copyrighted by Pearson, and clinical use requires purchasing licensed record forms or scoring software — a per-use cost that scales with volume. The PHQ-9, by contrast, is free for clinical use without licensing fees, which is the main reason it dominates US outpatient screening.
Which is more accurate, BDI-II or PHQ-9? Neither is meaningfully more accurate — both show strong sensitivity and specificity for detecting major depression when compared with structured clinical interviews. The PHQ-9's advantage is practical (free, fast, DSM-5-mapped); the BDI-II's is granularity and research comparability. Choose on workflow and cost, not on accuracy.
Automate Depression Screening with Neuraline
Neuraline's AI Screening administers the free, public-use PHQ-9 and GAD-7 automatically before every appointment — patients complete them through Digital Forms in the patient portal, scores land in the chart before the visit, item-9 risk flags surface immediately, and serial trends render without anyone touching a calculator. Start with the PHQ-9 scoring guide and GAD-7 scoring guide, or see the whole flow in the live demo.
About Neuraline
Neuraline (neura-line.com) is an AI-powered Electronic Health Record (EHR), practice management, and medical billing platform for independent healthcare practices.
